~~<i id='30E97408DA'><strike id='30E97408DA'><tt id='30E97408DA'><pre id='30E97408DA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：focus 2025-09-28 20:32:09 - browse：214

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： 'Patient friction coefficient' can gauge a clinical trial's patient burden

entertainment

hotspot

focus

BristolCEOChristopherBoernerBusinessWireviaAPSANFRANCISCO— ChristopherBoernerhasbeentheCEOofBristolM

WSS

CRISPR technology availability, affordability needs to be expanded

U.K. sequencing study surfaces new findings about tumor DNA

Pfizer, Moderna say biotech, pharma drug development is a sprint

How a scoliosis diagnosis changed the life of one young dancer

GSK Flovent asthma inhalers replaced by authorized generics

Chinese researcher claims birth of first gene

focus

leisure time

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

3 medical device trends to watch in 2024

New air purifier tech could be key to improving indoor air quality

Testing GLP

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How a scoliosis diagnosis changed the life of one young dancer

Wildfire smoke exposes gaps in outdoor worker protections

6 surprising facts about sugar

As demand for Covid shots wanes, Moderna seeks its next success

Asbestos ban is immediate, but health effects will linger for decades

hotspot

CRISPR technology availability, affordability needs to be expanded

Chronically ill young patients struggle to find fertility info

UCB departs biotech trade group BIO

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Ahead of JPM, here's who's profiting most in health care

Antibiotic resistance and the global rise in human conflict

hotspot

hotspot

hotspot

focus